{"schema_version":"secwatch.filing_event.v1","accession":"0001759425-25-000030","form_type":"8-K","ticker":"MIRM","cik":"0001759425","company_name":"Mirum Pharmaceuticals, Inc.","filed_at":"2025-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.613023+00:00","generated_at":"2026-05-22T08:37:22.397110+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Mirum Q1 revenue $111.6M; raises 2025 guidance to $435-450M","bullets":["Q1 2025 total revenue $111.6M vs $69.2M YoY, driven by LIVMARLI ($73.2M, +71%) and Bile Acid Medicines ($38.4M, +47%).","Raises full-year 2025 revenue guidance to $435-450M from prior range.","LIVMARLI oral tablet formulation approved by FDA; also approved in Japan for ALGS and PFIC.","VISTAS PSC study enrollment completion expected Q3 2025; topline data Q2 2026.","Cash and investments $298.6M as of March 31, 2025, up from $292.8M at year-end 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001759425-25-000030","json":"https://secwatch.observer/filing/0001759425-25-000030.json","markdown":"https://secwatch.observer/filing/0001759425-25-000030.md","text":"https://secwatch.observer/filing/0001759425-25-000030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1759425/000175942525000030/0001759425-25-000030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1759425/000175942525000030/mirm-20250507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T08:37:22.397110+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}